Recent Updates
Recently added Catalysts
USNA Positive Sentiment

USANA Health Sciences Reports Third Quarter 2026 Results

Tuesday, November 3, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: USANA Health Sciences reported its third quarter 2026 results, showing net sales of $206 million, down from $214 million in the same quarter last year. The company recorded a net loss of $(5.6) million, an improvement from $(6.5) million. Diluted EPS also improved to $(0.30) from $(0.36), indicating a positive trend in financial performance.

Market Sentiment Analysis

POSITIVE FACTORS

  • Net loss decreased from $(6.5) million to $(5.6) million.
  • Diluted EPS improved from $(0.36) to $(0.30).
  • Adjusted EBITDA remained relatively stable at $12.1 million.

Full Press Release Details

SALT LAKE CITY--(BUSINESS WIRE)--USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its fiscal third quarter ended October 3, 2026. Key Financial Results Third Quarter 2026 vs. Third Quarter 2025 Net sales of $206 million versus $214 million. Net loss of $(5.6) million versus $(6.5) million. Diluted EPS of $(0.30) as compared with $(0.36). Adjusted diluted EPS(1) of $(0.11) as compared with $(0.15). Adjusted EBITDA(2) of $12.1 million versus $13.8 million. Core Nutri

Frequently Asked Questions

What were USANA's net sales for Q3 2026?

USANA's net sales for Q3 2026 were $206 million.

How did USANA's net loss change from last year?

USANA's net loss decreased from $(6.5) million to $(5.6) million.

What was the diluted EPS for USANA in Q3 2026?

The diluted EPS for USANA in Q3 2026 was $(0.30).

What was USANA's adjusted EBITDA for Q3 2026?

USANA's adjusted EBITDA for Q3 2026 was $12.1 million.

ShareAdd on Google
Tags: USNA USANA Q3 2026 financial results net sales EPS
Last updated: Nov 3, 2026

Biotech snapshot

Cash runway
$169M liquidity · $0M/mo burn
Low dilution risk